# LL-37 (Cathelicidin) **Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/ll-37-cathelicidin **Data Source:** Hermetica Superfoods Ingredient Encyclopedia **Updated:** 2026-03-28 **Evidence Score:** 4 / 10 **Category:** Compound **Also Known As:** Cathelicidin antimicrobial peptide, hCAP-18, Human cationic antimicrobial protein 18, CAMP, Cathelicidin LL-37, CAP18, Antimicrobial peptide LL-37, Human cathelicidin, FALL-39, Protein CAMP ## Overview LL-37 (cathelicidin) is an [antimicrobial](/ingredients/condition/immune-support) peptide produced by immune cells that provides broad-spectrum protection against bacteria, viruses, and fungi. It works by disrupting pathogen membranes while modulating immune responses and promoting tissue repair through multiple cellular pathways. ## Health Benefits - Exhibits broad-spectrum antimicrobial activity, defending against bacteria, viruses, and fungi. - Supports [immune system](/ingredients/condition/immune-support) function by modulating inflammatory responses and enhancing pathogen clearance. - Promotes wound healing and tissue regeneration by stimulating angiogenesis and cellular repair. - Reduces chronic [inflammation](/ingredients/condition/inflammation) by balancing cytokine production, supporting overall health. - May help manage antibiotic-resistant infections by disrupting microbial biofilms. - Enhances skin barrier function, protecting against environmental stressors and irritants. - Supports gut health by maintaining a balanced [microbiome](/ingredients/condition/gut-health) and reducing harmful pathogens. - Offers potential benefits for autoimmune conditions by regulating immune tolerance. ## Mechanism of Action LL-37 disrupts microbial cell membranes through electrostatic interactions and pore formation, leading to pathogen death. The peptide modulates immune responses by binding to toll-like receptors (TLR2/4) and activating MAPK signaling pathways. It promotes angiogenesis and tissue repair by stimulating VEGF expression and enhancing fibroblast proliferation through EGFR activation. ## Clinical Summary Most research on LL-37 consists of in vitro and animal studies demonstrating [antimicrobial](/ingredients/condition/immune-support) efficacy against various pathogens. Limited human clinical trials have examined topical applications for wound healing, showing modest improvements in healing rates. Observational studies indicate deficient LL-37 levels are associated with increased infection susceptibility, particularly in immunocompromised patients. Clinical evidence for supplemental LL-37 remains preliminary and requires larger controlled trials. ## Nutritional Profile - Composed of a sequence of amino acids. - Administered via topical application or injection. - Acts on microbial membranes to disrupt pathogens. ## Dosage & Preparation Dosage varies based on application method and purpose. Consult a healthcare provider before use. ## Safety & Drug Interactions LL-37 supplementation safety data is limited due to minimal human clinical trials. Potential side effects may include local irritation when applied topically or [immune system](/ingredients/condition/immune-support) overstimulation with systemic use. No specific drug interactions have been documented, but caution is advised with immunosuppressive medications. Safety during pregnancy and breastfeeding is unknown, and use should be avoided without medical supervision. ## Scientific Research LL-37 has been studied in vitro and in animal models for its antimicrobial and [immunomodulatory](/ingredients/condition/immune-support) effects. Clinical trials are limited but ongoing. ## Historical & Cultural Context LL-37 was identified as part of the human innate [immune system](/ingredients/condition/immune-support) and has been researched for its potential in combating infections. ## Synergistic Combinations Vitamin C, Zinc, Echinacea ## Frequently Asked Questions ### What is LL-37 cathelicidin peptide? LL-37 is a 37-amino acid antimicrobial peptide naturally produced by neutrophils and epithelial cells. It serves as the body's primary cathelicidin antimicrobial peptide, providing first-line defense against bacterial, viral, and fungal infections. ### How does LL-37 kill bacteria and viruses? LL-37 kills pathogens by inserting into their cell membranes and forming pores that cause membrane disruption and cell death. Its positive charge allows it to bind to negatively charged microbial surfaces, making it effective against both gram-positive and gram-negative bacteria. ### Can LL-37 supplements boost immune function? While LL-37 naturally supports immune function, supplement effectiveness is not well-established in humans. Most studies showing immune benefits are from laboratory and animal research, with limited clinical trials in humans to confirm supplemental benefits. ### What conditions are associated with low LL-37 levels? Low LL-37 levels are linked to increased infection susceptibility, delayed wound healing, and certain autoimmune conditions like atopic dermatitis. Patients with chronic kidney disease, diabetes, and immunodeficiencies often show reduced LL-37 production. ### Is LL-37 available as a supplement? LL-37 is not widely available as a commercial supplement due to its peptide nature and stability issues. Most research uses synthetic LL-37 for laboratory studies, and therapeutic applications remain largely experimental with limited regulatory approval. ### What is the difference between LL-37 and other antimicrobial peptides? LL-37 is the only known human cathelicidin antimicrobial peptide, making it unique compared to other antimicrobial peptides like defensins that exist in multiple forms. While defensins are primarily found in immune cells, LL-37 is produced by neutrophils, epithelial cells, and other tissues, giving it broader distribution throughout the body. LL-37's dual ability to both directly kill pathogens and modulate immune signaling distinguishes it from peptides that function primarily through direct antimicrobial action alone. ### Does LL-37 supplementation affect the body's natural production of this peptide? Current research does not indicate that exogenous LL-37 supplementation suppresses the body's endogenous production, as the peptide is typically degraded relatively quickly in circulation. However, long-term effects on natural production have not been extensively studied in human trials. Supporting LL-37 production through vitamin D, zinc, and other cofactors may be a complementary approach, as these nutrients enhance the body's own synthesis of cathelicidin. ### How does LL-37 support skin health and wound healing differently than other wound-healing supplements? LL-37 promotes wound healing through multiple mechanisms including stimulating angiogenesis (new blood vessel formation), enhancing fibroblast activity, and reducing infection risk simultaneously. Unlike collagen or growth factor supplements that primarily support structural repair, LL-37 addresses both the antimicrobial environment and tissue regeneration signals needed for optimal healing. Its anti-inflammatory properties also help prevent excessive scarring while maintaining the immune defense needed during the healing process. --- *Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com* *License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*